The Recombinant Human NY-ESO-1 (HLA-A*02:01) Protein is a biologically active recombinant protein that plays a significant role in various cellular processes and signaling pathways in human biology. This protein is widely employed in immunological research, cell biology studies, protein-protein interaction analyses, and therapeutic development, providing researchers with a reliable tool for investigating NY-ESO-1 (HLA-A*02:01) function and its implications in health and disease.
This product (SKU: RPCB2178) is produced using HEK293 cells and features a C-His&Avi tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 50.5 kDa with an observed molecular weight of 55-60 kDa under denaturing conditions, achieving ≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC., ensuring exceptional quality and consistency for research applications.
High quality, high purity and low endotoxin recombinant Recombinant Human NY-ESO-1 (HLA-A*02:01) Protein (RPCB2178), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 1 EU/μg of the protein by LAL method.
Purity:
≥ 95 % as determined by Tris-Bis PAGE;≥ 95 % as determined by HPLC.
Reconstitution:
Centrifuge the tube before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
Recombinant Human NY-ESO-1 (HLA-A*02:01) Protein was determined by Tris-Bis PAGE under reducing conditions.
The purity of Human NY-ESO-1 (HLA-A*02:01) is greater than 95% as determined by SEC-HPLC.
